GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC

Bulletin Express

05/12

Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.

The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.

The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1191568096"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191568096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191568096?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191568096","market":"us","top_or_hot":-1,"title":"GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.</p>\n<p>The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.</p>\n<p>The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-05-12 19:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.</p>\n<p>The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.</p>\n<p>The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1191568096","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191568096","pubTimestamp":1778586213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物宣布传奇生物向美国SEC提交2026年第一季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.\nThe disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.\nThe Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}